PolyPeptide Group AG
Research PolyPeptide Group AG (PPGN) on Bullrun: market cap CHF 1.45B, P/E 107.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPPGN
- ExchangeSW
- CountrySwitzerland
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCHF
- Market capCHF 1.45B
- P/E107.2
- Financial periodFY2025
- RevenueEUR 391.87M
- Revenue growth15.7%
- Net income-EUR 21.17M
- Free cash flow-EUR 31.40M
- Gross margin17.0%
Valuation Snapshot
latest market cap is CHF 1.45B; P/E is 107.2.
Peer valuation comparison
Latest P/E is 107.2x versus a Healthcare sector median of 24.46x (338.2% above).
Latest P/E is 107.2x versus a Switzerland median of 20.32x (427.6% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 391.87M | -EUR 21.17M | -EUR 31.40M | 17.0% | -0.64 | EUR 74.59M | EUR 130.57M | EUR 340.60M |
| FY2024 | EUR 338.70M | -EUR 19.56M | EUR 2.43M | 11.6% | -0.59 | EUR 68.28M | EUR 94.12M | EUR 357.24M |
| FY2023 | EUR 324.77M | -EUR 51.44M | -EUR 20.25M | 2.8% | -1.56 | EUR 95.71M | EUR 113.66M | EUR 381.23M |
| FY2022 | EUR 283.29M | EUR 7.77M | -EUR 73.30M | 19.2% | 0.24 | EUR 37.53M | EUR 21.22M | EUR 421.68M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | CHF 1.45B | 107.2 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CHF.
| Year | Dividends/share |
|---|---|
| FY2022 | 0.3 EUR |
About PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PolyPeptide Group AG's market cap?
PolyPeptide Group AG's market capitalization is CHF 1.45B.
What is PolyPeptide Group AG's P/E ratio?
PolyPeptide Group AG's price-to-earnings (P/E) ratio is 107.2.
What does PolyPeptide Group AG do?
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, pharmaceutical, and biotech companies.